Bo Liu

Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)

David C. Tully, Paul V. Rucker, D. CHIANELLI et al. · Journal of Medicinal Chemistry · 2017 · 224 citations · Full text

Pathology, Farnesoid X Receptor, Pharmacotherapy +20

Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters

Lulu Sun, Yuanyuan Pang, Xuemei Wang et al. · Acta Pharmaceutica Sinica B · 2019 · 194 citations · Full text

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 6. Structure−Activity Studies of Orally Bioavailable, 2-Pyridone-Containing Peptidomimetics

Peter S. Dragovich, Thomas J. Prins, Ru Zhou et al. · Journal of Medicinal Chemistry · 2002 · 140 citations · Full text

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 8. Pharmacological Optimization of Orally Bioavailable 2-Pyridone-Containing Peptidomimetics

Peter S. Dragovich, Thomas J. Prins, Ru Zhou et al. · Journal of Medicinal Chemistry · 2003 · 113 citations

Pharmacotherapy, Antiviral Drug, Molecular Pharmacology +17

A high-throughput assay for assessing the cell permeability of combinatorial libraries

Peng Yu, Bo Liu, Thomas Kodadek · Nature Biotechnology · 2005 · 110 citations

Combinatorial Libraries, Membrane Transport, Bioanalysis +12